HC Wainwright Has Positive Estimate for PolyPid Q2 Earnings

PolyPid Ltd. (NASDAQ:PYPD) – Equities research analysts at HC Wainwright increased their Q2 2026 EPS estimates for PolyPid in a research report issued on Tuesday, July 21st. HC Wainwright analyst B. Folkes now expects that the company will earn ($0.36) per share for the quarter, up from their prior estimate of ($0.38). HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.34) per share. HC Wainwright also issued estimates for PolyPid’s Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($0.84) EPS, FY2028 earnings at ($0.40) EPS, FY2029 earnings at $0.80 EPS and FY2030 earnings at $1.64 EPS.

PolyPid (NASDAQ:PYPD) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.12.

Other equities research analysts also recently issued research reports about the company. Craig Hallum set a $12.00 target price on PolyPid in a research report on Wednesday. Weiss Ratings upgraded PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 23rd. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $11.33.

PolyPid Stock Performance

Shares of PYPD opened at $4.24 on Thursday. The firm has a market capitalization of $80.90 million, a price-to-earnings ratio of -2.22 and a beta of 1.40. The business’s fifty day moving average price is $4.85 and its two-hundred day moving average price is $4.58. PolyPid has a 52 week low of $3.06 and a 52 week high of $5.73.

Institutional Trading of PolyPid

A number of institutional investors have recently bought and sold shares of PYPD. AIGH Capital Management LLC lifted its stake in shares of PolyPid by 18.7% in the 1st quarter. AIGH Capital Management LLC now owns 1,593,587 shares of the company’s stock valued at $6,980,000 after purchasing an additional 250,615 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of PolyPid during the fourth quarter worth $451,000. XTX Topco Ltd grew its stake in shares of PolyPid by 50.0% during the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock worth $142,000 after purchasing an additional 10,888 shares during the period. Renaissance Technologies LLC bought a new stake in PolyPid in the first quarter valued at about $81,000. Finally, Jane Street Group LLC bought a new stake in PolyPid in the fourth quarter valued at about $66,000. Institutional investors and hedge funds own 26.47% of the company’s stock.

Key Headlines Impacting PolyPid

Here are the key news stories impacting PolyPid this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $13.00 price target on PolyPid, which can help reinforce investor confidence in the stock’s upside potential.
• Positive Sentiment: The firm also raised near-term Q2 2026 EPS estimates and slightly improved its Q4 2026 EPS forecast, signaling modestly better expectations for execution in the coming quarters.
• Neutral Sentiment: HC Wainwright’s broader note updated multiple forward estimates across FY2026-FY2030, keeping attention on PolyPid’s long-term path to profitability. Article Title
• Negative Sentiment: Some longer-dated earnings forecasts were cut, including FY2027, FY2028, FY2029, and FY2030 EPS estimates, which suggests analysts still see a bumpy road to sustained earnings growth. Article Title

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.